ZYNYZ (RETIFANLIMAB-DLWR)
ZYNYZ (RETIFANLIMAB-DLWR) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: ZYNYZ; Generic name: RETIFANLIMAB-DLWR; Drug class: Programmed Death Receptor-1 Blocking Antibody [EPC].
| Brand name | ZYNYZ |
|---|---|
| Generic name | RETIFANLIMAB-DLWR |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Manufacturer | Incyte Corporation |
| Used for | 1 INDICATIONS AND USAGE ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal (SCAC) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). ( 1.1 ) as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. ( 1.1 ) Merkel Cell Carcinoma (MCC) for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). ( 1.2 ) 1.1 Squamous Cell Carcinom |
| Dosage | 2 DOSAGE AND ADMINISTRATION Administer ZYNYZ as an intravenous infusion over 30 minutes after dilution ( 2.3 ): For Squamous Cell Carcinoma of the Anal Canal (SCAC), in combination with carboplatin and paclitaxel, or as a single agent ( 2.1 ): 500 mg every 4 weeks, or 375 mg every 3 weeks For Merkel Cell Carcinoma (MCC) ( 2.1 ): 500 mg every 4 weeks See full prescribing information for dosage modifications for adverse reactions ( 2.2 ) and preparation and administration instructions. ( 2.3 ) 2.1 |
| Active ingredient(s) | RETIFANLIMAB |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=109648d0-d30a-42fc-8273-39cb1540a751 |